The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Sued by Malaysia Hospital Group over TOB Interference
November 28, 2023
- Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
- Sumitomo Wins Approval for Antibiotic Xenleta in China
November 24, 2023
- Otsuka’s UK Unit Astex to Receive Milestone Payment from AstraZeneca
November 24, 2023
- Lilly Restricts Shipments of Humalog, Lyumjev in Spillover from Novo’s Insulin Curb
November 22, 2023
- Alfresa Boosts Biz Alliance with Major Chinese Wholesaler
November 22, 2023
- BMS Japan Has Busy Years Ahead with String of Launches towards Doubling of Sales
November 22, 2023
- Daiichi Sankyo Wins ADC Patent Row against Seagen, Appeals Unfavorable Ruling in Enhertu Suit
November 21, 2023
- Janssen Files FGFR Inhibitor Erdafitinib for Urothelial Cancer in Japan
November 21, 2023
- Lagevrio Japan’s Top-Seller Drug in July-September, 2 Other COVID Meds Make Top 10: IQVIA
November 20, 2023
- Santen Snags European OK for Glaucoma/Ocular Hypertension Drug
November 20, 2023
- Xtandi Approved in US for Prostate Cancer in Earlier Setting
November 20, 2023
- Janssen Files Bispecific Antibody Amivantamab for NSCLC in Japan
November 20, 2023
- Takeda Files CMV Drug Maribavir in Japan
November 20, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- Astellas to Acquire US Upstart Propella for Prostate Cancer Drug
November 17, 2023
- Japanese Pricing Rules Don’t Fully Capture Value of New Modalities, “No” to CEA Expansion: Janssen Exec
November 17, 2023
- Novo Nordisk Curbs Insulin Shipments Due to Surge in Demand for Diabetes Meds
November 17, 2023
- Astellas, University of Tsukuba Tie Up in Drug Discovery and Startup Incubation
November 17, 2023
- Xocova, Dayvigo Again Winner in Sept Rep Promotion Rankings for GPs, HPs: Intage
November 17, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…